Veritas Genetics, which offers accessible genetic testing, has raised $30m (£24m) in Series B funding. The company, founded in 2014, sequences whole genomes for $999 (£814) and also offers tests for hereditary cancer and reproductive health. In a statement, the company said it was “excited to be working with such an innovative group of partners who are committed to advancing human health through genomic research”. The round was led by Trustbridge Partners and Jiangsu Simcere Pharmaceutical, with participation from existing investor Lilly Asia Ventures.
Veritas Genetics, which offers accessible genetic testing, has raised $30m (£24m) in Series B funding. The company, founded in 2014, sequences whole genomes for $999 (£814) and also offers tests for hereditary cancer and reproductive health. The funding will be used to add to Veritas Genetics' product portfolio, increase its digital tools for customers and build partnerships in the health industry. The round was led by Trustbridge Partners and Jiangsu Simcere Pharmaceutical, with participation from existing investor Lilly Asia Ventures.